~~<i id='03AF56B1A3'><strike id='03AF56B1A3'><tt id='03AF56B1A3'><pre id='03AF56B1A3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：Wikipedia 2025-09-30 12:10:26 - browse：5726

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Vaccine advisory panel ACIP left half staffed by HHS

explore

entertainment

knowledge

focus

hotspot

entertainment

CourtesyPfizerThenewvaccinesthatprotectolderadultsagainstrespiratorysyncytialvirus,orRSV,maybelinked

WSS

A Q&A with Aletha Maybank, AMA’s chief health equity officer

RSV vaccines may be linked to small increased risk of developing GBS

FogPharma raises $145 million in rare Series E round

In search for therapies for solid tumors, companies turn to claudin

Medicare Advantage proposed rates disappoint insurers

Why getting cancer drugs just got harder for rural patients

hotspot

focus

explore

ChatGPT in medicine: STAT answers readers' burning questions

Medical mystery: When a cough is not just a cough

In age of alternative facts, a scholarly course on calling out crap

RaDonda Vaught to speak at CommonSpirit event on patient safety

Trump demands the U.S. pay no more for drugs than other countries … again

House looks to weaken Medicare negotiation

Supreme Court strikes down use of affirmative action

FDA does about

New air purifier tech could be key to improving indoor air quality

A Q&A with Aletha Maybank, AMA’s chief health equity officer

entertainment

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

AstraZeneca loses challenge to Medicare drug price negotiation

Biotech companies concerned about China biosecurity crackdown

Gilead might be held responsible for not developing a drug

Biden report: The neurospychology of memory and aging

Medical device lobby: We're tired of waiting on Medicare coverage

knowledge

focus

hotspot

entertainment